Naomi Lambert

Mrs. Naomi Lambert

Research, Regenative Labs, Pensacola, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ALAlbert Lai
Albert Lai
CTConrad Tamea
Conrad Tamea
JSJohn Shou
John Shou
AOAnthony Okafor
Anthony Okafor
JSJay Sparks
Jay Sparks
TBTyler Barrett
Tyler Barrett
Background: Osteoarthritis is a chronic disorder that affects the synovial joints by the progressive loss of articular cartilage. In the hip, the largest weight-bearing joint, the deterioration of articular cartilage and acetabular labrum can cause pain, diminishing the quality of life for patients. This study presents changes in reported pain scales from patients who received Wharton’s jelly applications to cartilage deterioration in the hip from the observational retrospective repository at Regenative Labs. Methods: Sixty-nine patients were selected based on inclusion criteria with patient-reported pain scales, including the Numeric Pain Rating Scale and the Western Ontario and McMaster University Osteoarthritis Index, collected at the initial application, 30, and 90-day follow-up visits. Thirteen patients received a second allograft application and had additional follow-up visits at 120 and 180 days. Results: Five of the six scales used showed a statistically significant improvement in average scores across the cohort. The greatest improvements were observed in the NPRS with a 31.36% improvement after 90 days and a 44.64% improvement for patients with two applications after 180 days. The minimal clinically important difference (MCID) was also calculated to determine the perceived value of care for each patient with 44.9% of patients exceeding the MCID and 78.3% reporting at least one level of improvement. Conclusions: The positive outcomes for the patients in this cohort suggest WJ to be a promising alternative care option for patients with structural tissue degeneration in the hip refractory to the current standard of care.

22 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ALAlbert Lai
Albert Lai
CTConrad Tamea
Conrad Tamea
JSJohn Shou
John Shou
AOAnthony Okafor
Anthony Okafor
JSJay Sparks
Jay Sparks
TBTyler Barrett
Tyler Barrett
With the increasing occurrence of rotator cuff injuries every year, there is a great need for a reliable treatment option. Wharton’s Jelly contains several components that can positively impact the replacement and repair of musculoskeletal defects. The overall objective of this study is to evaluate the improvement of patient-reported pain scales after applying Wharton’s Jelly (WJ) in rotator cuff defects. Eighty-seven patients with rotator cuff defects who failed at least eight weeks of conservative treatment were selected from the retrospective repository. A total of 2 cc of WJ flowable allograft was applied to the specific affected anatomy, the most common being supraspinatus tendon, biceps tendon insertion, labral tear, and subscapularis tear. No adverse reactions were reported. Statistically significant improvements were found from the initial to Day 90 in all scales. Patient satisfaction was calculated using minimal clinically important differences. No statistically significant differences were found in mean changes between gender, BMI, and age. Scanning electron microscopy images reveal the similarities between the collagen matrix in WJ and the rotator cuff. The significant improvement in patient outcomes coincides with the current literature analyzing WJ applications with other structural defects around the body. WJ is a promising alternative for musculoskeletal defects when the standard of care fails.

21 February 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ALAlbert Lai
Albert Lai
CTConrad Tamea
Conrad Tamea
JSJohn Shou
John Shou
AOAnthony Okaf
Anthony Okaf
JSJay Sparks
Jay Sparks
TBTyler Chadd Barrett
Tyler Chadd Barrett
With the increasing occurrence of rotator cuff injuries every year, there is a great need for a reliable treatment option. Wharton’s Jelly contains several components that can positively impact the replacement and repair of musculoskeletal defects. The overall objective of this study is to evaluate the improvement of patient-reported pain scales after applying Wharton’s Jelly (WJ) in rotator cuff defects. Eighty-seven patients with rotator cuff defects who failed at least eight weeks of conservative treatment were selected from the retrospective repository. 2cc of WJ flowable allograft was applied to the specific affected anatomy, the most common being supraspinatus tendon, biceps tendon insertion, labral tear, and subscapularis tear. No adverse reactions were reported. Statistically significant improvements were found from the initial to Day 90 in all scales. Patient satisfaction was calculated using minimal clinically important differences. No statistically significant differences were found in mean changes between gender, BMI, and age. Scanning Electron Microscopy images reveal the similarities between the collagen matrix in WJ and the rotator cuff. The significant improvement in patient outcomes coincides with current literature analyzing WJ applications with other structural defects around the body. WJ is a promising alternative for musculoskeletal defects when the standard of care fails.

30 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
BBBabak Baravarian
Babak Baravarian
GKGi Kwon
Gi Kwon
JSJohn Shou
John Shou
NLNaomi Lambert
Naomi Lambert
ALAlexis Lee
Alexis Lee
TBTyler Barrett
Tyler Barrett
Introduction: Posterior tibial tendon dysfunction (PTTD) is a progressive degenerative tendinopathy often unresponsive to conservative care, necessitating surgical interventions with significant postoperative risks. Wharton’s jelly (WJ) tissue allograft from the human umbilical cord, with its collagen-rich matrix homologous to tendon tissue, presents a potential alternative intervention. This study aims to report preliminary findings on the safety and efficacy of WJ allografts for the supplementation of degenerated tissue in patients with PTTD. Material and Methods: Twenty-six patients from the observational repository were identified with PTTD (Stages II-IV) and failed at least three months of conservative care. Patients received one or two ultrasound-guided percutaneous applications of the WJ allograft. Outcomes were tracked using the Numeric Pain Rating Scale (NPRS), the Western Ontario and McMaster University Arthritis Index (WOMAC), and the Quality-of-Life Scale (QOLS) at the initial, 30, 90, and 120-day follow-ups. Results: The cohort was 62% male (n = 16) and 38% female (n = 10), with a mean age predominantly in the 70–89 range. From the initial to final visit (90 days for single applications, 120 days for double applications), the single-application group (n = 22) showed a 48.32% improvement in NPRS and a 22.73% improvement in total WOMAC. The double-application group (n = 8) showed a 50% improvement in NPRS and a 27.86% improvement in total WOMAC. A statistically significant improvement in NPRS was observed in the single-application group (p = 0.042). No adverse events were reported. Discussion: This study provides preliminary evidence that WJ tissue allografts may be a safe and effective minimally invasive application for degeneration of the PTT, which is associated with improvements in pain, function, and quality of life. Key limitations include a lack of a control group and a small cohort size. Conclusions: The positive findings of this study warrant further research through randomized controlled trials to confirm efficacy, establish optimal dosage, and compare WJ to other conservative interventions.

1 January 2025 in Archives of Clinical and Biomedical Research
Verified
Journal Article
Open access
PDF file
KRKenneth Russ
Kenneth Russ
PYPhilip Yoo
Philip Yoo
NLNaomi Lambert
Naomi Lambert
ALAlexis Lee
Alexis Lee
JSJohn Shou
John Shou
TBTyler Barrett
Tyler Barrett
Background/Objectives: Knee osteoarthritis (OA) is a progressive and disabling musculoskeletal disorder characterized by the degeneration of joint cartilage, leading to reduced range of motion and diminished quality of life. Globally, knee OA is estimated to account for approximately 80% of all osteoarthritis cases. The current standard of care is to provide conservative treatment with medication and lifestyle changes, but when they fail, surgical intervention may be required. Approximately 69% of patients with knee OA undergo total knee replacement surgery. Methods: The patient in this case study is an 85-year-old female who failed standard conservative care, presenting with advanced knee OA, poor posture, and an antalgic gait. The patient opted for regenerative medicine-focused care prior to seeking surgical intervention. The protocol included several regenerative therapies, pulsed electromagnetic field therapy (PEMF), myofascial release therapy, red lightemitting diode treatment (red light therapy), and a connective tissue transplant with a Wharton’s jelly tissue allograft. Results: Prior to treatment, the patient reported extreme pain. At the 3-month follow-up, she noted substantial pain reduction, and by the 12-month mark, reported complete resolution of pain. At a 5-year follow-up, the patient continued to report the absence of knee pain. Conclusions: This study observes the sustained improvement in pain and functional outcomes following a multimodal care approach. Aligning complementary regenerative protocols to target root causes instead of focusing on symptom management could improve outcomes-based care practices and should be further studied.

30 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
BBBabak Baravarian
Babak Baravarian
GKGi Kwon
Gi Kwon
JSJohn Shou
John Shou
NLNaomi Lambert
Naomi Lambert
ALAlexis Lee
Alexis Lee
TBTyler Barrett
Tyler Barrett
Introduction: Posterior tibial tendon dysfunction (PTTD) is a specific form of enthesopathy characterized by progressive degeneration and dysfunction of the posterior tibial tendon, often presenting with inflammation, tendon thickening, and pain along the foot. Current standard-of-care procedures produce many risks and complications, especially in operative care, highlighting the need for a favorable alternative medicine. Wharton’s jelly (WJ) possesses a collagen-rich matrix similar to tendons that can supplement tendon defects. This study aims to report supportive preliminary findings from patient-reported scales after WJ applications to patients with PTTD refractory to standard care. Materials and Methods: Twenty-six patients from the observational repository were identified with posterior tibial tendon defects who failed three months of conservative care. Patients received either a single application or two sequential applications based on the severity of their condition. The patient-reported results utilized the Numeric Pain Rating Scale (NPRS), the Western Ontario and McMaster University Arthritis Index (WOMAC), and the Quality of Life Scale (QOLS). WJ tissue allografts were applied to the structural defects in the posterior tibial tendon. No adverse events were reported. Results: Patients were categorized according to the number of applications they received. The percent improvement of each category was calculated from their initial visit to their final visit. Each dosage category observed improvement. Discussion: This study confirms that the application of WJ tissue allografts in treatment-resistant PTTD is beneficial, safe, and minimally invasive, providing preliminary evidence for utilizing WJ as an alternative method to current standard practices. Several limitations in this study included the lack of direct comparison groups with other conventional interventions and recall bias. Conclusion: The positive findings of this study indicate the need for further research to establish the best dosage protocols for Wharton’s jelly in patients suffering from PTTD.